Table 2 hVEGF concentrations, platelet counts and trough bevacizumab concentrations in patients 9–22
Patient number | Tumour type | VEGF concentration C1 (pg ml−1) | VEGF concentration on-treatment (pg ml−1) | Platelet count C1 (× 109 l−1) | Platelet count on-treatment (× 109 l−1) | Bevacizumab concentration ( μ g ml−1) |
|---|---|---|---|---|---|---|
9 | Breast | 781.2 | 169.9 | 428 | 372 | 68.3 |
10 | Breast | 425.5 | 129 | 195 | 248 | 85.3 |
11 | Breast | 1136.7 | 87.1 | 386 | 275 | 98.8 |
12 | Breast | 288.5 | 171.3 | 217 | 262 | 137.9 |
13 | Breast | 435.7 | 204.5 | 173 | 120 | 104.8 |
14 | Breast | 104.8 | 197.4 | 207 | 206 | 119.6 |
15 | Breast | 218.3 | 218 | 220 | 236 | 78.5 |
16 | Breast | 207 | 134.9 | 316 | 364 | 86.9 |
17 | Breast | 671.9 | 167.7 | 288 | 396 | 178.6 |
18 | Breast | 67.3 | 176.2 | 327 | 321 | 92.4 |
19 | Breast | 1492.3 | 21.3 | 261 | 419 | 424.1 |
20 | Breast | 3277.1 | 215.4 | 533 | 612 | 97.5 |
21 | Breast | 890.7 | 146.7 | 476 | 396 | 94.1 |
22 | Breast | 1101.6 | 220.1 | 294 | 259 | 104.1 |
Mean (±s.d.) | 792.8 (±836.1) | 161.4 (±55.7) | 320.4 (±110.9) | 320.4 (±119.5) | 126.5 (±90.0) |
